Europe Transient Protein Expression Market Forecast to 2031 - Regional Analysis - by Product Type, Application, and End User

Description

List of Tables

The Europe transient protein expression market was valued at US$ 247.78 million in 2023 and is expected to reach US$ 386.23 million by 2031; it is estimated to register a CAGR of 5.7% from 2023 to 2031.

Increasing Applications of Protein Expression Systems Drive Europe Transient Protein Expression Market

Animal and plant cell-based transient protein expression systems have been in use for the last three decades. Significant advancements in proteomics in recent years have resulted in the availability of newer recombinant protein varieties. The practicality and reproducibility of transient protein expression in animal and plant cells encourage research and development activities to extend their applications in human cell lines. Many contract research and development organizations as well as biopharmaceutical companies, among others, have focused their efforts on incorporating transient protein expression into their production processes. This type of expression system allows them to use different genes to create recombinant proteins without relying on the development of stable cell lines.

Temporary protein expression process finds widespread application in the manufacturing of growth factors, cytokines, hormones, blood products, modified human proteins, and monoclonal antibodies. Moreover, the creation and use of effective bioprocessing techniques have become essential for the commercial synthesis of recombinant proteins with significant therapeutic value. Recent developments in the field of bioprocessing are being applied to provide efficient methods for generating recombinant proteins. Modern Quality by Design concepts, continuous upstream processing, continuous chromatography, integrated continuous bioprocessing, high-throughput devices for efficient bioprocess optimization, disposable systems, and process analytics technologies for higher yields of high-quality products are among the recent developments.

Transient protein expression platforms are increasingly being used in vaccine development applications since the onset of the COVID-19 pandemic. Various researchers began studying the SARS-CoV-2 and its variants extensively by using transient protein expression systems. For instance, in March-April 2020, Absolute Antibody (UK) scaled up the production of multigram quantities of different anti-SARS-CoV-2 spike proteins to aid in the development of neutralizing antibodies. Similarly, transient protein expression systems were widely used to produce positive control proteins as a part of the in-vitro diagnostics kits development processes. Thus, the increasing applications of protein expression systems fuel the transient protein expression market growth.

Europe Transient Protein Expression Market Overview

The Europe transient protein expression market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy are expected to account for a significant share of the market in the region during the forecast period. The transient protein expression market in countries such as France, the UK, and Spain is likely to experience lucrative opportunities in the upcoming years. Growing R&D activities, rising adoption of newer techniques in biotech research, and increasing investments in the biotechnology sectors drive the transient protein expression market in Europe.

Europe Transient Protein Expression Market Revenue and Forecast to 2031 (US$ Million)

Europe Transient Protein Expression Market Segmentation

The Europe transient protein expression market is categorized into product type, application, end user, and country.

Based on product type, the Europe transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held the largest market share in 2023.

In terms of application, the Europe transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development. The genomic research segment held the largest market share in 2023.

Based on end user, the Europe transient protein expression market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment held the largest market share in 2023.

By country, the Europe transient protein expression market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe transient protein expression market share in 2023.

Thermo Fisher Scientific Inc, Merck KGaA, QIAGEN NV, GenScript Biotech Corporation, Promega Corp, Takara Bio Inc, New England Biolabs, Agilent Technologies Inc, Mirus Bio LLC, Bio-Rad Laboratories Inc, Lonza Group AG, and MaxCyte Inc are some of the leading companies operating in the Europe transient protein expression market.

Product Code: TIPRE00022177

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Europe Transient Protein Expression Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Increasing Applications of Protein Expression Systems
- 4.1.2 Surging Popularity of Precision Medicine
4.2 Market Restraints
- 4.2.1 High Cost of Products
4.3 Market Opportunities
- 4.3.1 Plant-Based Expression Systems for Therapeutic Protein Production
4.4 Future Trends
- 4.4.1 Integration of Artificial Intelligence (AI) and Automation Technologies
4.5 Impact of Drivers and Restraints:

5. Transient Protein Expression Market - Europe Analysis

5.1 Europe Transient Protein Expression Market Revenue (US$ Million), 2021-2031
5.2 Europe Transient Protein Expression Market Forecast Analysis

6. Europe Transient Protein Expression Market Analysis - by Product Type

6.1 Instruments
- 6.1.1 Overview
- 6.1.2 Instruments: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
6.2 Reagents
- 6.2.1 Overview
- 6.2.2 Reagents: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Expression Vectors
- 6.3.1 Overview
- 6.3.2 Expression Vectors: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Competent Cells
- 6.4.1 Overview
- 6.4.2 Competent Cells: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Transient Protein Expression Market Analysis - by Application

7.1 Genomic Research
- 7.1.1 Overview
- 7.1.2 Genomic Research: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Gene Therapy
- 7.2.1 Overview
- 7.2.2 Gene Therapy: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Bio production
- 7.3.1 Overview
- 7.3.2 Bio production: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Cancer Research
- 7.4.1 Overview
- 7.4.2 Cancer Research: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Drug Development
- 7.5.1 Overview
- 7.5.2 Drug Development: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Transient Protein Expression Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Academic and Research Institutes
- 8.2.1 Overview
- 8.2.2 Academic and Research Institutes: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Clinical Research Organizations
- 8.3.1 Overview
- 8.3.2 Clinical Research Organizations: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Transient Protein Expression Market - Country Analysis

9.1 Europe
- 9.1.1 Europe Transient Protein Expression Market Overview
- 9.1.2 Europe Transient Protein Expression Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.1 Europe Transient Protein Expression Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.2 Germany: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.2.2.1 Germany: Europe Transient Protein Expression Market Breakdown, by Product Type
    - 9.1.2.2.2 Germany: Europe Transient Protein Expression Market Breakdown, by Application
    - 9.1.2.2.3 Germany: Europe Transient Protein Expression Market Breakdown, by End User
  - 9.1.2.3 United Kingdom: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.2.3.1 United Kingdom: Europe Transient Protein Expression Market Breakdown, by Product Type
    - 9.1.2.3.2 United Kingdom: Europe Transient Protein Expression Market Breakdown, by Application
    - 9.1.2.3.3 United Kingdom: Europe Transient Protein Expression Market Breakdown, by End User
  - 9.1.2.4 France: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.2.4.1 France: Europe Transient Protein Expression Market Breakdown, by Product Type
    - 9.1.2.4.2 France: Europe Transient Protein Expression Market Breakdown, by Application
    - 9.1.2.4.3 France: Europe Transient Protein Expression Market Breakdown, by End User
  - 9.1.2.5 Italy: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.2.5.1 Italy: Europe Transient Protein Expression Market Breakdown, by Product Type
    - 9.1.2.5.2 Italy: Europe Transient Protein Expression Market Breakdown, by Application
    - 9.1.2.5.3 Italy: Europe Transient Protein Expression Market Breakdown, by End User
  - 9.1.2.6 Spain: Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.2.6.1 Spain: Europe Transient Protein Expression Market Breakdown, by Product Type
    - 9.1.2.6.2 Spain: Europe Transient Protein Expression Market Breakdown, by Application
    - 9.1.2.6.3 Spain: Europe Transient Protein Expression Market Breakdown, by End User
  - 9.1.2.7 Rest of Europe Transient Protein Expression Market - Revenue and Forecast to 2031 (US$ Million)
    - 9.1.2.7.1 Rest of Europe Transient Protein Expression Market Breakdown, by Product Type
    - 9.1.2.7.2 Rest of Europe Transient Protein Expression Market Breakdown, by Application
    - 9.1.2.7.3 Rest of Europe Transient Protein Expression Market Breakdown, by End User

10. Competitive Landscape

10.1 Company Positioning & Concentration

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in Europe Transient Protein Expression Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Thermo Fisher Scientific Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Merck KGaA
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 QIAGEN NV
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 GenScript Biotech Corporation
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Promega Corp
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Takara Bio Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 New England Biolabs
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Agilent Technologies Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Mirus Bio LLC
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Bio-Rad Laboratories Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
12.11 Lonza Group AG
- 12.11.1 Key Facts
- 12.11.2 Business Description
- 12.11.3 Products and Services
- 12.11.4 Financial Overview
- 12.11.5 SWOT Analysis
- 12.11.6 Key Developments
12.12 MaxCyte Inc
- 12.12.1 Key Facts
- 12.12.2 Business Description
- 12.12.3 Products and Services
- 12.12.4 Financial Overview
- 12.12.5 SWOT Analysis
- 12.12.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms